Choi Woo Hee, Han Eun Ji, O Joo Hyun, Choi Eun Kyoung, Choi Joon-Il, Park Gyeongsin, Choi Byung-Ock, Jeon Young-Woo, Min Gi-June, Cho Seok-Goo
Division of Nuclear Medicine, Department of Radiology, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Department of Radiology, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Diagnostics (Basel). 2023 Sep 1;13(17):2834. doi: 10.3390/diagnostics13172834.
This study evaluated the prognostic significance of FDG PET/CT in patients with nodal peripheral T-cell lymphoma (PTCL). We retrospectively reviewed patients with histologically confirmed nodal PTCL who underwent FDG PET/CT at baseline, after three cycles of first-line chemotherapy (interim), and at the end of therapy. Response was assessed visually using the Deauville 5-point scale (D5PS); scores of 1, 2, and 3 were considered PET-negative, and scores of 4 and 5 were considered PET-positive. The associations between FDG PET/CT findings and survival were assessed using Cox regression analysis. A total of 79 patients (44 males and 35 females; median age 56 years) were included in this study. In response assessment, 17 (22%) had an interim PET-positive result and 10 (13%) had an end-of-therapy PET-positive result. During a median follow-up of 50 months, 37 patients (47%) presented with disease progression and 30 patients (38%) died. The estimated 5-year progression-free survival (PFS) and overall survival (OS) were 57% and 64%, respectively. An interim PET-positive result was the only significant indicator of PFS. Higher International Prognostic Index and end-of-therapy PET-positive result were significant independent prognostic factors of OS. Interim and end-of-therapy FDG PET/CT responses based on D5PS are meaningful in predicting the outcomes of patients with nodal PTCL.
本研究评估了氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（FDG PET/CT）在淋巴结外周T细胞淋巴瘤（PTCL）患者中的预后意义。我们回顾性分析了组织学确诊为淋巴结PTCL且在基线、一线化疗三个周期后（中期）以及治疗结束时接受FDG PET/CT检查的患者。使用多维尔5分制（D5PS）进行视觉评估反应；1分、2分和3分被视为PET阴性，4分和5分被视为PET阳性。使用Cox回归分析评估FDG PET/CT结果与生存之间的关联。本研究共纳入79例患者（44例男性和35例女性；中位年龄56岁）。在反应评估中，17例（22%）中期PET结果为阳性，10例（13%）治疗结束时PET结果为阳性。在中位随访50个月期间，37例患者（47%）出现疾病进展，30例患者（38%）死亡。估计的5年无进展生存期（PFS）和总生存期（OS）分别为57%和64%。中期PET阳性结果是PFS的唯一显著指标。较高的国际预后指数和治疗结束时PET阳性结果是OS的显著独立预后因素。基于D5PS的中期和治疗结束时FDG PET/CT反应在预测淋巴结PTCL患者的预后方面具有意义。
